Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy.

被引：1

作者：

Borad, Mitesh J.

Davis, Sarah Lindsey

Lowery, Maeve Aine

Lihou, Christine F.

Abou-Alfa, Ghassan K.

机构：

[1] Mayo Clin, Scottsdale, AZ USA

[2] Univ Colorado, Anschutz Med Campus, Aurora, CO USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Incyte Corp, Wilmington, DE USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS4145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4145

引用

页数：6